Cipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Margin is expected to drop significantly in FY26 and FY27, with concerns about finding a suitable buyer after Torrent's acquisition of JB Chemicals. While Cipla is pursuing new respiratory and complex generic assets, analysts doubt these will fully offset Revlimid's decline.